Skip to main content

Generic Tazverik Availability

Last updated on Oct 6, 2021.

Tazverik is a brand name of tazemetostat, approved by the FDA in the following formulation(s):

TAZVERIK (tazemetostat hydrobromide - tablet;oral)

  • Manufacturer: EPIZYME INC
    Approval date: January 23, 2020
    Strength(s): EQ 200MG BASE [RLD]

Has a generic version of Tazverik been approved?

No. There is currently no therapeutically equivalent version of Tazverik available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tazverik. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Aryl- or heteroaryl-substituted benzene compounds
    Patent 10,155,002
    Issued: December 18, 2018
    Assignee(s): Epizyme, Inc.

    The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

    Patent expiration dates:

    • April 13, 2032
      ✓ 
      Patent use: METHOD OF TREATING EPITHELIOID SARCOMA
  • Salt form of a human histone methyltransferase EZH2 inhibitor
    Patent 10,245,269
    Issued: April 2, 2019
    Assignee(s): Epizyme, Inc. Eisai R&D Management Co., Ltd.

    Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.

    Patent expiration dates:

    • April 11, 2033
      ✓ 
      Patent use: METHOD OF TREATING EPITHELIOID SARCOMA BY INHIBITING ENHANCER OF ZESTE HOMOLOG 2 (EZH2)
    • April 11, 2033
      ✓ 
      Patent use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION BY INHIBITING EZH2
    • April 11, 2033
      ✓ 
      Patent use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA BY INHIBITING EZH2
  • Patent 10,369,155

    Patent expiration dates:

    • October 16, 2035
      ✓ 
      Patent use: METHOD OF TREATING EPITHELIOID SARCOMA
    • October 16, 2035
      ✓ 
      Patent use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
    • October 16, 2035
      ✓ 
      Patent use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
  • Patent 10,420,775

    Patent expiration dates:

    • April 13, 2032
      ✓ 
      Patent use: METHOD OF TREATING EPITHELIOID SARCOMA
    • April 13, 2032
      ✓ 
      Patent use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
    • April 13, 2032
      ✓ 
      Patent use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
  • Patent 10,786,511

    Patent expiration dates:

    • December 19, 2035
      ✓ 
      Drug product
  • Salt form of a human histone methyltransferase EZH2 inhibitor
    Patent 10,821,113
    Issued: November 3, 2020
    Assignee(s): Epizyme, Inc. Eisai R&D Management Co., Ltd.

    Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.

    Patent expiration dates:

    • April 11, 2033
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Patent 11,052,093

    Patent expiration dates:

    • April 13, 2032
      ✓ 
      Patent use: METHOD OF TREATING FOLLICULAR LYMPHOMA
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • April 13, 2032
      ✓ 
      Patent use: METHOD OF TREATING EPITHELIOID SARCOMA
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Aryl- or heteroaryl-substituted benzene compounds
    Patent 8,410,088
    Issued: April 2, 2013
    Assignee(s): Epizyme, Inc. Eisai R&D Management Co., Ltd.

    The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

    Patent expiration dates:

    • April 13, 2032
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Inhibitors of human EZH2 and methods of use thereof
    Patent 8,691,507
    Issued: April 8, 2014
    Assignee(s): Epizyme, Inc.

    The invention relates to determining the presence of an EZH2 gene mutation in a sample from a subject and inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono-through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2, such that trimethylation of H3-K27, which is associated with certain cancers, is inhibited. The methods can be used to treat cancers including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Also provided are methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and also methods for determining responsiveness to an EZH2 inhibitor in a subject.

    Patent expiration dates:

    • September 12, 2031
      ✓ 
      Patent use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
  • Aryl- or heteroaryl-substituted benzene compounds
    Patent 8,765,732
    Issued: July 1, 2014
    Assignee(s): Epizyme, Inc.

    The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

    Patent expiration dates:

    • April 13, 2032
      ✓ 
      Patent use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
    • April 13, 2032
      ✓ 
      Patent use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
  • Inhibitors of human EZH2 and methods of use thereof
    Patent 8,895,245
    Issued: November 25, 2014
    Assignee(s): Epizyme, Inc.

    The invention relates to inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono- through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2, such that trimethylation of H3-K27, which is associated with certain cancers, is inhibited. The methods can be used to treat cancers including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Also provided are methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and also methods for determining responsiveness to an EZH2 inhibitor in a subject.

    Patent expiration dates:

    • September 12, 2031
      ✓ 
      Patent use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
  • Aryl- or heteroaryl-substituted benzene compounds
    Patent 9,090,562
    Issued: July 28, 2015
    Assignee(s): Epizyme, Inc.

    The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

    Patent expiration dates:

    • April 13, 2032
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Inhibitors of human EZH2, and methods of use thereof
    Patent 9,175,331
    Issued: November 3, 2015
    Assignee(s): Epizyme, Inc.

    The invention relates to inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono- through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2, such that trimethylation of H3-K27, which is associated with certain cancers, is inhibited. The methods can be used to treat cancers including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Also provided are methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and also methods for determining responsiveness to an EZH2 inhibitor in a subject.

    Patent expiration dates:

    • September 12, 2031
      ✓ 
      Patent use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
  • Inhibitors of human EZH2, and methods of use thereof
    Patent 9,333,217
    Issued: May 10, 2016
    Assignee(s): Epizyme, Inc.

    The invention relates to inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono- through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2, such that trimethylation of H3-K27, which is associated with certain cancers, is inhibited. The methods can be used to treat cancers including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Also provided are methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and also methods for determining responsiveness to an EZH2 inhibitor in a subject.

    Patent expiration dates:

    • September 12, 2031
      ✓ 
      Patent use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
  • Inhibitors of human EZH2, and methods of use thereof
    Patent 9,334,527
    Issued: May 10, 2016
    Assignee(s): Epizyme, Inc.

    The invention relates to inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono- through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2, such that trimethylation of H3-K27, which is associated with certain cancers, is inhibited. The methods can be used to treat cancers including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Also provided are methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and also methods for determining responsiveness to an EZH2 inhibitor in a subject.

    Patent expiration dates:

    • September 12, 2031
      ✓ 
      Patent use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
  • Salt form of a human histone methyltransferase EZH2 inhibitor
    Patent 9,394,283
    Issued: July 19, 2016
    Assignee(s): Epizyme, Inc. Eisai R&D Management Co., LTD.

    Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.

    Patent expiration dates:

    • April 11, 2033
      ✓ 
      Patent use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • April 11, 2033
      ✓ 
      Patent use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
      ✓ 
      Drug substance
      ✓ 
      Drug product
  • Aryl- or heteroaryl-substituted benzene compounds
    Patent 9,522,152
    Issued: December 20, 2016
    Assignee(s): Epizyme, Inc.

    The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

    Patent expiration dates:

    • April 13, 2032
      ✓ 
      Patent use: METHOD OF TREATING A LUNG METASTASIS OF EPITHELIOID SARCOMA
  • Aryl- or heteroaryl-substituted benzene compounds
    Patent 9,549,931
    Issued: January 24, 2017
    Assignee(s): Epizyme, Inc.

    The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

    Patent expiration dates:

    • April 13, 2032
      ✓ 
      Patent use: METHOD OF TREATING EPITHELIOID SARCOMA
    • April 13, 2032
      ✓ 
      Patent use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
    • April 13, 2032
      ✓ 
      Patent use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
  • Methods of treating cancer
    Patent 9,688,665
    Issued: June 27, 2017
    Assignee(s): Epizyme, Inc.

    The present invention relates to methods of treating cancer by administering the EZH2 inhibitor compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

    Patent expiration dates:

    • August 22, 2034
      ✓ 
      Patent use: METHOD OF TREATING EPITHELIOID SARCOMA
  • Aryl-or heteroaryl-substituted benzene compounds
    Patent 9,855,275
    Issued: January 2, 2018
    Assignee(s): Epizyme, Inc.

    The present invention relates to aryl- or heteroaryl-substituted benzene compounds. The present invention also relates to pharmaceutical compositions containing these compounds and methods of treating cancer by administering these compounds and pharmaceutical compositions to subjects in need thereof. The present invention also relates to the use of such compounds for research or other non-therapeutic purposes.

    Patent expiration dates:

    • April 13, 2032
      ✓ 
      Patent use: METHOD OF TREATING EPITHELIOID SARCOMA
  • Salt form of a human histone methyltransferase EZH2 inhibitor
    Patent 9,872,862
    Issued: January 23, 2018
    Assignee(s): Epizyme, Inc. Eisai R&D Management Co., Ltd.

    Provided herein is N-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl (tetrahydro-2H-pyran-4-yl)amino)-4-methyl-4′-(morpholinomethyl)-[1,1′-biphenyl]-3-carboxamide hydrobromide. Also provided herein is a particular polymorph form of this compound.

    Patent expiration dates:

    • April 11, 2033
      ✓ 
      Patent use: METHOD OF TREATING A LUNG METASTASIS OF EPITHELIOID SARCOMA
  • Method for treating cancer
    Patent 9,889,138
    Issued: February 13, 2018
    Assignee(s): Epizyme, Inc.

    The present invention provides a method for treating or alleviating a symptom of a disorder, e.g., immune evasion, cancer-cell induced immune dysfunction, reduced immune response, lowered inflammation, decreased expression of a major histocompatibility complex (MHC), or cancer, characterized by aberrant, misregulated, or increased Enhancer of Zeste Homolog 2 (EZH2) activity in a cell or subject in need thereof by contacting the cell or administering to the subject a therapeutically effective amount of an EZH2 inhibitor.

    Patent expiration dates:

    • October 16, 2035
      ✓ 
      Patent use: METHOD OF TREATING EPITHELIOID SARCOMA
    • October 16, 2035
      ✓ 
      Patent use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION
    • October 16, 2035
      ✓ 
      Patent use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA
  • Inhibitors of human EZH2, and methods of use thereof
    Patent 9,949,999
    Issued: April 24, 2018
    Assignee(s): Epizyme, Inc.

    The invention relates to inhibition of wild-type and certain mutant forms of human histone methyltransferase EZH2, the catalytic subunit of the PRC2 complex which catalyzes the mono- through tri-methylation of lysine 27 on histone H3 (H3-K27). In one embodiment the inhibition is selective for the mutant form of the EZH2, such that trimethylation of H3-K27, which is associated with certain cancers, is inhibited. The methods can be used to treat cancers including follicular lymphoma and diffuse large B-cell lymphoma (DLBCL). Also provided are methods for identifying small molecule selective inhibitors of the mutant forms of EZH2 and also methods for determining responsiveness to an EZH2 inhibitor in a subject.

    Patent expiration dates:

    • September 12, 2031
      ✓ 
      Patent use: METHOD OF TREATING RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA POSITIVE FOR AN ENHANCER OF ZESTE HOMOLOG 2 (EZH2) MUTATION BY INHIBITING EZH2

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • June 18, 2023 - TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) WHOSE TUMORS ARE POSITIVE FOR AN EZH2 MUTATION AS DETECTED BY AN FDA-APPROVED TEST AND WHO HAVE RECEIVED AT LEAST 2 PRIOR SYSTEMIC THERAPIES
    • June 18, 2023 - TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) WHO HAVE NO SATISFACTORY ALTERNATIVE TREATMENT OPTIONS
    • January 23, 2025 - NEW CHEMICAL ENTITY
    • January 23, 2027 -
    • June 18, 2027 -

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.